• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Benralizumab does not reduce the rate of acute COPD exacerbations

byDevin MillerandStefan Trela
September 9, 2014
in Chronic Disease, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients treated with benralizumab did not experience a reduced annual rate of acute COPD exacerbations.

2. However, benralizumab treatment conferred clinically significant improvement in lung function as shown by increased pre- and post-bronchodilator FEV1.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic obstructive pulmonary disease (COPD) is a lung disorder marked by airway obstruction and chronically poor airflow. In a subset of 10-20% of COPD patients, obstruction is thought to be brought on by eosinophilic irritation of the airways. Interleukin-5 (IL-5) is a regulatory cytokine for the survival and proliferation of eosinophils. Benralizumab, a humanized antibody to interleukin-5 receptor α, has been shown to reduce blood and sputum eosinophil counts. This study assessed the safety and efficacy of benralizumab in decreasing the rate of acute COPD exacerbations in patients with pre-existing sputum eosinophilia. Clinical measures such as forced expiratory volume in one second (FEV1) as well as patient questionnaires were utilized to examine treatment efficacy.

The results showed that benralizumab did not reduce the annual rate of acute COPD exacerbations when compared to placebo. Measurement of efficacy using patient questionnaires proved non-significant as well. However, benralizumab decreased blood and sputum levels of eosinophils and significantly improved lung function as shown by an increased pre- and post-bronchodilator FEV1 compared to placebo. The study was limited by its small sample size as the lack of a sufficient number of patients underpowered several analyses carried out by the authors. Additionally, although the rate of COPD exacerbations was analyzed there was no attempt to define the causes of these events. The authors concluded that although benralizumab did not reduce acute COPD exacerbations, it was effective in improving other measures such as lung function, which supports further investigation of benralizumab in patients with eosinophilic COPD.

This study was funded by MedImmune.

Click to read the study, published today in The Lancet Respiratory Medicine

RELATED REPORTS

Pulmonary arterial pruning and longitudinal change in percent emphysema and lung function

#VisualAbstract: Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

Relevant Reading: Exacerbation rate, health status and mortality in COPD–a review of potential interventions

In-Depth [randomized controlled trial]: This phase 2a study included 101 adult patients aged 40-85 years with moderate-to-severe COPD, with 82 included in the per-protocol population. Inclusion criteria were defined as at least one acute COPD exacerbation in the past year, present or past smokers with a 10+ pack-year history, a post-bronchodilator FEV1 <80% predicted, a FEV1 to forced vital capacity ratio of <70%, and a sputum eosinophil count of >3.0% for 12 months prior to or at screening. Patients were block randomized to receive either 100mg benralizumab (n=40) or placebo (n=42) subcutaneously every 4 weeks for 3 doses, then every 8 weeks for 5 doses over 48 weeks. The primary endpoint was annualized rate of moderate and severe acute COPD exacerbations at week 56.

Benralizumab did not reduce the annualized rate of COPD exacerbations (0.95, 95% Confidence Interval [CI] 0.68–1.29) compared to the placebo group (0.92, 0.67–1.25). However, patients receiving benralizumab experienced a significant reduction in blood and sputum eosinophil percentages at weeks 4 and 8 of treatment, respectively. Additionally, benralizumab significantly improved pre-bronchodilator FEV­1 vs. placebo (-0.06L [SD 0.24] vs. 0.13L [0.41], p=0.014) and post-bronchodilator FEV1 vs. placebo (-0.08 L [SD 0.21] vs 0.09 L [0.39], p=0.014). No significant differences were noted between groups for SGRQ-C, CRQ-SAS, or BODE questionnaire scores. 45 (88%) patients reported treatment-emergent adverse effects and 14 (27%) patients reported serious adverse effects in the benralizumab group vs. 41 (82%) and 9 (18%) in the placebo group. The most common adverse events were respiratory disorders and infections. Two (4%) patients in the benrazlizumab group died during the study (one due to myocardial infarction, and the other suddenly from an unknown cause), but the authors did not consider either to be related to benralizumab treatment. One (2%) patient in the placebo group died from bronchitis after study completion.

More from this author: Lifetime diabetes risk rises as incidence increases and mortality decreases, Early alteplase treatment leads to better stroke outcomes regardless of age or stroke severity, Improved hematologic cancer survival in Europe over a 15 year period [EUROCARE-5 study], Vitamin D may reduce the risk of hypertension, Schizophrenia linked with higher rates of violence, suicide, and early mortality

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Benralizumabcopd
Previous Post

USPSTF recommends aspirin for women at risk for preeclampsia

Next Post

Arterial catheter monitoring in ICU not associated with mortality benefit

RelatedReports

2 Minute Medicine Rewind May 20, 2019
Pulmonology

Pulmonary arterial pruning and longitudinal change in percent emphysema and lung function

February 24, 2021
#VisualAbstract: Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for maintenance of HIV-1 viral suppression
StudyGraphics

#VisualAbstract: Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

January 6, 2021
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Infectious Disease

Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

December 27, 2020
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Benralizumab not shown to ameliorate COPD exacerbation rates when compared to placebo

May 25, 2019
Next Post
Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Arterial catheter monitoring in ICU not associated with mortality benefit

Diffusion tensor imaging valuable in the evaluation of peripheral neuropathy

Fish oil lowers seizure frequency in drug-resistant epilepsy

Dexamethasone shows comparable efficacy to prednisone/prednisolone in pediatric asthma

Intermittent montelukast (singulair) fails to reduce medical visits in children with wheezing [WAIT trial]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.